Getinib (IressaTM, AstraZeneca) is a well-known inhibitor of the tyrosine kinase epidermal
growth factor receptor (EGFR), active in patients affected by non-small cell lung cancer …

Gefitinib (IressaTM), an orally-active tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR), is the first approved molecular-targeted drug for the management of …

Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …

Gefitinib has a modest activity in previously treated patients with advanced non-small cell
lung cancer (NSCLC). However, the efficacy and safety of gefitinib monotherapy in untreated …

7099 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain,
has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). The clinical …

Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …

19136 Background: Although chemotherapy improves survival in advanced NSCLC
patients, it appears to have reached a therapeutic plateau and novel approaches are …

7059 Background: Gefitinib is active for recurrent NSCLC after platinum-based
chemotherapy (Fukuoka M, et al. J Clin Oncol 21: 2237, 2003. Kris MG, et al. JAMA 290 …

To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa™) in patients
with refractory non—small-cell lung cancer (NSCLC) treated in a community-based setting …

Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth
factor receptor (EGFR), which had antitumor activity in patients with previously treated non …